Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2012 1
2018 1
2019 2
2020 3
2021 10
2022 10
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 ACS Investigators. Watanabe H, et al. JAMA Cardiol. 2022 Apr 1;7(4):407-417. doi: 10.1001/jamacardio.2021.5244. JAMA Cardiol. 2022. PMID: 35234821 Free PMC article. Clinical Trial.
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, Ando K, Ono K, Kadota K, Suwa S, Morishima I, Yoshida R, Hata Y, Akao M, Yagi M, Suematsu N, Morino Y, Yokomatsu T, Takamisawa I, Noda T, Doi M, Okayama H, Nakamura Y, Hibi K, Sakamoto H, Noguchi T, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. J Am Coll Cardiol. 2024 Jan 2;83(1):17-31. doi: 10.1016/j.jacc.2023.10.013. Epub 2023 Oct 23. J Am Coll Cardiol. 2024. PMID: 37879491 Clinical Trial.
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. JAMA. 2019 Jun 25;321(24):2414-2427. doi: 10.1001/jama.2019.8145. JAMA. 2019. PMID: 31237644 Free PMC article. Clinical Trial.
Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention.
Yamamoto K, Shiomi H, Morimoto T, Miyazawa A, Watanabe H, Nakamura S, Suwa S, Domei T, Ono K, Sakamoto H, Shigetoshi M, Taniguchi R, Okayama H, Yokomatsu T, Muto M, Kawaguchi R, Kishi K, Hadase M, Fujita T, Nishida Y, Nishino M, Otake H, Natsuaki M, Watanabe H, Suematsu N, Tanabe K, Abe M, Hibi K, Kadota K, Ando K, Kimura T; OPTIVUS-Complex PCI Investigators. Yamamoto K, et al. Circ J. 2023 Oct 25;87(11):1661-1671. doi: 10.1253/circj.CJ-23-0141. Epub 2023 May 16. Circ J. 2023. PMID: 37197941 Free article.
Target Lesion Revascularization After Intravascular Ultrasound-Guided Percutaneous Coronary Intervention.
Yamamoto K, Shiomi H, Morimoto T, Miyazawa A, Watanabe H, Natsuaki M, Watanabe H, Yamaji K, Ohya M, Nakamura S, Mitomo S, Suwa S, Domei T, Tatsushima S, Ono K, Sakamoto H, Shimamura K, Shigetoshi M, Taniguchi R, Nishimoto Y, Okayama H, Matsuda K, Yokomatsu T, Muto M, Kawaguchi R, Kishi K, Hadase M, Fujita T, Nishida Y, Nishino M, Otake H, Suematsu N, Ajimi T, Tanabe K, Abe M, Hibi K, Kadota K, Ando K, Kimura T; OPTIVUS-Complex PCI Investigators*. Yamamoto K, et al. Circ Cardiovasc Interv. 2023 May;16(5):e012922. doi: 10.1161/CIRCINTERVENTIONS.123.012922. Epub 2023 May 16. Circ Cardiovasc Interv. 2023. PMID: 37192307
Single-Session Versus Staged Multivessel Optimal IVUS-Guided PCI in Patients With CCS or NSTE-ACS.
Yamamoto K, Shiomi H, Morimoto T, Miyazawa A, Watanabe H, Nakamura S, Suwa S, Domei T, Ono K, Sakamoto H, Shigetoshi M, Taniguchi R, Okayama H, Toyota T, Yokomatsu T, Muto M, Kawaguchi R, Kishi K, Hadase M, Fujita T, Nishida Y, Nishino M, Otake H, Natsuaki M, Watanabe H, Suematsu N, Tanabe K, Abe M, Hibi K, Kadota K, Ando K, Kimura T; OPTIVUS-Complex PCI Investigators. Yamamoto K, et al. JACC Asia. 2023 Jun 13;3(4):649-661. doi: 10.1016/j.jacasi.2023.03.013. eCollection 2023 Aug. JACC Asia. 2023. PMID: 37614540 Free PMC article.
Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI.
Yamamoto K, Watanabe H, Morimoto T, Obayashi Y, Natsuaki M, Domei T, Yamaji K, Suwa S, Isawa T, Watanabe H, Yoshida R, Sakamoto H, Akao M, Hata Y, Morishima I, Tokuyama H, Yagi M, Suzuki H, Wakabayashi K, Suematsu N, Inada T, Tamura T, Okayama H, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 and STOPDAPT-2 ACS Investigators. Yamamoto K, et al. JACC Asia. 2023 Jan 10;3(1):31-46. doi: 10.1016/j.jacasi.2022.09.011. eCollection 2023 Feb. JACC Asia. 2023. PMID: 36873770 Free PMC article.
Polypharmacy and Bleeding Outcomes After Percutaneous Coronary Intervention.
Yamamoto K, Morimoto T, Natsuaki M, Shiomi H, Ozasa N, Sakamoto H, Takeji Y, Domei T, Tada T, Taniguchi R, Uegaito T, Yamada M, Takeda T, Eizawa H, Suwa S, Shirotani M, Tamura T, Inoko M, Sakai H, Ishii K, Toyofuku M, Miki S, Onodera T, Furukawa Y, Inada T, Ando K, Kadota K, Nakagawa Y, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators. Yamamoto K, et al. Circ J. 2023 Sep 15. doi: 10.1253/circj.CJ-23-0558. Online ahead of print. Circ J. 2023. PMID: 37722886 Free article.
Coronary Artery Disease Without Standard Cardiovascular Risk Factors.
Yamamoto K, Natsuaki M, Morimoto T, Shiomi H, Takeji Y, Yamaji K, Matsumura-Nakano Y, Yoshikawa Y, Yamamoto E, Fuki M, Kato E, Yamashita Y, Yaku H, Nakatsuma K, Watanabe H, Matsuda M, Tamura T, Inoko M, Mabuchi H, Shirotani M, Eizawa H, Ishii K, Inada T, Onodera T, Shinoda E, Yamamoto T, Toyofuku M, Takahashi M, Sakamoto H, Miki S, Aoyama T, Suwa S, Sato Y, Furukawa Y, Ando K, Kadota K, Nakagawa Y, Kimura T; Credo-Kyoto PCI/CABG Registry Investigators. Yamamoto K, et al. Am J Cardiol. 2022 Feb 1;164:34-43. doi: 10.1016/j.amjcard.2021.10.032. Epub 2021 Nov 28. Am J Cardiol. 2022. PMID: 34852931
29 results